Multiple Myeloma Clinical Trials in Georgia

Cancer Type = Multiple Myeloma

Cancer Type = Multiple Myeloma

There are currently 45 active Multiple Myeloma clinical trials in Georgia.
2.
A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT01464034
Protocol IDs
AMyC 10-MM-01
IST-CAR-521
PO-MM-PI-0034
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
9.
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03287908
Protocol IDs
20170122
NCI-2017-02084
2017-001997-41
10.
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Cancer Type
Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03424603
Protocol IDs
STRO-001-BCM1
NCI-2018-00484
11.
A Phase 1 Study of bb21217, an Anti-BCMA CAR T Cell Drug Product, in Relapsed and / or Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03274219
Protocol IDs
CRB-402
NCI-2017-01861
12.
A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects With Relapsed or Refractory Haematologic Malignancies
Cancer Type
Hodgkin Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03218683
Protocol IDs
D6910C00001
NCI-2017-01390
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
13.
A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03361748
Protocol IDs
BB2121-MM-001
NCI-2017-02488
U1111-1202-5554
2017-002245-29
16.
A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT02833610
Protocol IDs
15-571
NCI-2016-01375
17.
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects With High-Risk Smoldering Multiple Myeloma
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03301220
Protocol IDs
CR108172
NCI-2018-00062
2016-001205-16
54767414SMM3001
18.
NCORP Trial
A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03651128
Protocol IDs
BB2121-MM-003
NCI-2018-02057
U1111-1217-9988
2018-001023-38
Treatment Sites (2)
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
21.
A Phase I Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT01794520
Protocol IDs
M13-367
2012-000589-38
22.
A Phase I Study of FOR46 Administered Every 21 Days in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Cancer Type
Lymphoma, Multiple Myeloma
NCI ID
NCT03650491
Protocol IDs
FOR46-002
NCI-2018-02600
Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.